Free Trial

Allogene Therapeutics (ALLO) News Today

Allogene Therapeutics logo
$1.82 -0.02 (-1.09%)
As of 01/17/2025 04:00 PM Eastern
Zacks Research Issues Pessimistic Outlook for ALLO Earnings
Allogene Therapeutics, Inc. stock logo
Zacks Research Issues Pessimistic Estimate for ALLO Earnings
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Investment analysts at Zacks Research lowered their Q2 2025 earnings per share (EPS) estimates for Allogene Therapeutics in a note issued to investors on Thursday, January 9th. Zacks Research analyst R. Department now expects that the comp
Allogene Therapeutics, Inc. stock logo
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) have received a consensus rating of "Moderate Buy" from the ten research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and ni
Allogene Therapeutics, Inc. stock logo
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Holdings Boosted by Geode Capital Management LLC
Geode Capital Management LLC grew its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 14.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,227,104 shares of the company's st
Allogene Therapeutics, Inc. stock logo
State Street Corp Sells 655,041 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)
State Street Corp cut its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 8.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,013,083 shares of the company's stock after selling 655,041 shares dur
Allogene Therapeutics, Inc. stock logo
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Rating of "Moderate Buy" by Analysts
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twelve brokerages that are covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and nine have issued
Allogene Therapeutics, Inc. stock logo
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Update
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 31,170,000 shares, a decrease of 11.1% from the November 15th total of 35,050,000 shares. Based on an average daily volume of 2,260,000 shares, the days-to-cover ratio is currently 13.8 days.
Allogene acknowledges passing of founding board member David Bonderman
Piper Sandler Remains a Buy on Allogene Therapeutics (ALLO)
Allogene Therapeutics, Inc. stock logo
516,601 Shares in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Acquired by Zacks Investment Management
Zacks Investment Management purchased a new position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 516,601 shares of the company's stock, valued at approx
Allogene Therapeutics, Inc. stock logo
Fmr LLC Cuts Stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
Fmr LLC cut its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 3.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,026,956 shares of the company's stock after
Allogene Therapeutics, Inc. stock logo
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Down 5.4% in November
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) was the recipient of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 35,050,000 shares, a drop of 5.4% from the October 31st total of 37,040,000 shares. Based on an average daily volume of 2,160,000 shares, the days-to-cover ratio is presently 16.2 days.
Allogene Therapeutics, Inc. stock logo
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Sold by Vestal Point Capital LP
Vestal Point Capital LP lowered its stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 31.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,500,000 shares of
Allogene Therapeutics, Inc. stock logo
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendati
Allogene Therapeutics presents data for ALLO-329 in autoimmune disease
Allogene Therapeutics, Inc. stock logo
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Sees Significant Decrease in Short Interest
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) saw a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 37,040,000 shares, a drop of 5.8% from the October 15th total of 39,320,000 shares. Approximately 26.7% of the shares of the company are sold short. Based on an average trading volume of 1,980,000 shares, the short-interest ratio is currently 18.7 days.
Piper Sandler Sticks to Its Buy Rating for Allogene Therapeutics (ALLO)
Allogene Therapeutics, Inc. stock logo
Allogene Therapeutics (NASDAQ:ALLO) Shares Down 6.3% on Analyst Downgrade
Allogene Therapeutics (NASDAQ:ALLO) Trading Down 6.3% on Analyst Downgrade
Allogene Therapeutics, Inc. stock logo
Allogene Therapeutics (NASDAQ:ALLO) Given New $9.00 Price Target at Piper Sandler
Piper Sandler decreased their target price on Allogene Therapeutics from $11.00 to $9.00 and set an "overweight" rating on the stock in a research report on Thursday.
JMP Securities Remains a Hold on Allogene Therapeutics (ALLO)
Allogene Therapeutics, Inc. stock logo
Allogene Therapeutics (NASDAQ:ALLO) Given "Buy" Rating at HC Wainwright
HC Wainwright reaffirmed a "buy" rating and issued a $9.00 price target on shares of Allogene Therapeutics in a report on Friday.
RBC Capital Keeps Their Buy Rating on Allogene Therapeutics (ALLO)
Allogene announces Phase 1 data on ALLO-316 in advanced RCC
Allogene Therapeutics to present data on ALLO-316 at IKCS, SITC meetings
Allogene Therapeutics, Inc. stock logo
Allogene Therapeutics (NASDAQ:ALLO) Trading 6.3% Higher - Time to Buy?
Allogene Therapeutics (NASDAQ:ALLO) Trading 6.3% Higher - Here's What Happened
Allogene Therapeutics, Inc. stock logo
Allogene Therapeutics (ALLO) Set to Announce Earnings on Thursday
Allogene Therapeutics (NASDAQ:ALLO) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.
Allogene Therapeutics, Inc. stock logo
Allogene Therapeutics' (ALLO) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $9.00 price target on shares of Allogene Therapeutics in a research report on Wednesday.
Get Allogene Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.

ALLO Media Mentions By Week

ALLO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ALLO
News Sentiment

-0.06

0.68

Average
Medical
News Sentiment

ALLO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ALLO Articles
This Week

7

3

ALLO Articles
Average Week

Get Allogene Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ALLO) was last updated on 1/18/2025 by MarketBeat.com Staff
From Our Partners